Tarsus Pharmaceuticals
Website: tarsusrx.com
Product: XDEMVY (lotilaner ophthalmic solution) 0.25%
About Tarsus
Tarsus Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing the development and commercialization of therapeutic candidates to address highly prevalent diseases with limited treatment options across a range of therapeutic categories including eye care and infectious disease prevention. Their lead product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, is FDA-approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05, an oral tablet for the prevention of Lyme disease. Learn more at TarsusRx.com.
About our XDEMVY
XDEMVY is indicated for the treatment of Demodex blepharitis. Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis. For additional information, please see full prescribing information available at: xdemvy.com.
